Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CareDx, Inc. - Common Stock (NQ:CDNA)

14.47 +0.19 (+1.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CareDx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer
From CareDx, Inc.
Via Business Wire
CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure
From CareDx, Inc.
Via Business Wire
CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors
From CareDx, Inc.
Via Business Wire
CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025
From CareDx, Inc.
Via Business Wire
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting
From CareDx, Inc.
Via Business Wire
CareDx Issues Comment Letter on Draft LCD Policy
From CareDx, Inc.
Via Business Wire
CareDx to Participate in Wells Fargo Healthcare Conference
From CareDx, Inc.
Via Business Wire
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
From CareDx, Inc.
Via Business Wire
CareDx Announces Second Quarter 2025 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
From CareDx, Inc.
Via Business Wire
CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress
From CareDx, Inc.
Via Business Wire
CareDx to Report Second Quarter 2025 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection
From CareDx, Inc.
Via Business Wire
CareDx Announces Repurchase of 5% of Outstanding Shares
From CareDx, Inc.
Via Business Wire
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
From Johnson Fistel, PLLP
Via Business Wire
CareDx to Participate in Upcoming Investor Conferences
From CareDx, Inc.
Via Business Wire
CareDx Reports First Quarter 2025 Results
From CareDx, Inc.
Via Business Wire
CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting
From CareDx, Inc.
Via Business Wire
CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx to Report First Quarter 2025 Financial Results
From CareDx, Inc.
Via Business Wire
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
From Kahn Swick & Foti, LLC
Via Business Wire
CareDx Launches Two Expanded Indications for AlloSure Testing Services
From CareDx, Inc.
Via Business Wire
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
From Kahn Swick & Foti, LLC
Via Business Wire
CareDx Announces Fourth Quarter and Full Year 2024 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict
From CareDx, Inc.
Via Business Wire
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
From Johnson Fistel, LLP
Via Business Wire
CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies
From CareDx, Inc.
Via Business Wire
CareDx to Report Fourth Quarter and Full Year 2024 Financial Results
From CareDx, Inc.
Via Business Wire
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
From CareDx, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.